#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Endometroidní adenokarcinom s metastázou v křížovém obratli


Autoři: Lorayne Cardoso Gontijo 1 ;  Renata Margarida Etchebehere 2 ;  Luís Ronan Marquez Ferreira de Souza 3 ;  Eddie Fernando Candido Murta 1 ;  Rosekeila Simões Nomelini 1,4
Působiště autorů: Laboratory of Applied Sciences for Women (LaCam)/ Department of Gynecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba-MG, Brazil 1;  Surgical Pathology Service, Federal University of Triângulo Mineiro, Uberaba-MG, Brazil 2;  Discipline of Radiology, Federal University of Triângulo Mineiro, Uberaba-MG, Brazil 3;  Graduate Program in Gynecology and Obstetrics of the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil 4
Vyšlo v časopise: Ceska Gynekol 2024; 89(4): 298-303
Kategorie: Kazuistika
doi: https://doi.org/10.48095/cccg2024298

Souhrn

Většina nádorů kostí jsou metastázy. Primární nádory, které tvoří metastázy v kostech, se nejčastěji vyskytují v prsu, plicích, ledvinách a štítné žláze. Tato případová studie popisuje pacientku s výskytem nádoru kosti v osové kostře, původně v křížové oblasti. Primární místo nebylo určeno. Vyšetření tedy bylo nutné rozšířit o imunohistochemii, která prokázala metastatický nádor kompatibilní s endometroidním adenokarcinomem, nicméně ani po vyšetřeních nebyla v oblasti endometria nalezena aktivní léze. Tato studie byla observační a popisná, s cílem rozebrat důležitost přesnějších vyšetřovacích metod. V tomto směru imunohistochemie vyniká jako precizní metoda schopná optimalizovat diagnózu, léčbu a následně i prognózu.

Klíčová slova:

imunohistochemie – novotvar kostí – endometrioidní adenokarcinom


Zdroje

1. Macedo F, Ladeira K, Pinho F et al. Bone metastases: an overview. Oncol Rev 2017; 11 (1): 321. doi: 10.4081/oncol.2017.321.

2. Shibata H, Kato S, Sekine I et al. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open 2016; 1 (2): e000037. doi: 10.1136/esmo open-2016-000037.

3. Hacker NF. Uterine cancer. In: Berek JS, Hacker NF (eds). Practical gynecologic oncology. Philadelphia, PA: Lippincott Williams & Wilkins 2005: 397–442.

4. Albareda J, Herrera M, Lopez Salva A et al. Sacral metastasis in a patient with endometrial cancer: case report and review of the literature. Gynecol Oncol 2008; 111 (3): 583–588. doi: 10.1016/j.ygyno.2008.04.005.

5. NIH-USA National Cancer Institute, Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Uterine Cancer. 2023 [online]. Available from: https: //seer.cancer.gov/statfacts/html/corp.html.

6. Sorosky JI. Endometrial cancer. Obstet Gynecol 2012; 120 (2 Part 1): 383–397. doi: 10.1097/ aog.0b013e3182605bf1.

7. ACOG (American College of Obstetricians and Gynecologists). Committee on Gynecologic Practice. Society of Gynecologic Oncology. 2020 [online]. Available from: https: //www.acog.org/clinical/clinical-guidance/committee-opinion.

8. Bedner R, Rzepka-Górska I. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. Eur J Gynaecol Oncol 2007; 28 (5): 400–402.

9. ACOG (American College of Obstetricians and Gynecologists). The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion No. 440. 2018 [online]. Available from: https: //www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/05/the-role-of-transvaginal-ultrasonography-in-evaluating-the-endometrium-of-women-with-postmenopausal-bleeding.

10. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105 (2): 103–104. doi: 10.1016/j.ijgo.2009.02.012.

11. Weiss LM, Chu P, Schroeder BE et al. Blinded comparator study of immunohistochemical analysis versus 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn 2013; 15 (2): 263–269. doi: 10.1016/j.jmoldx.2012.10.001.

12. Werner M, Chott A, Fabiano A et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24 (7): 1016–1019. doi: 10.1097/00000 478-200007000-00014.

13. Kandalaft PL, Gown AM. Practical applications in immunohistochemistry: carcinomas of unknown primary site. Arch Pathol Lab Med 2016; 140 (6): 508–523. doi: 10.5858/arpa. 2015-0173-CP.

14. McCluggage WG, Palaniappan Sumathi V, McBride HA et al. Panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002; 21 (1): 11–15. doi: 10.1097/00004347-200201000-00003.

15. Ordóñez NG.Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol 2012; 19 (3): 140–151. doi: 10.1097/ PAP.0b013e318253465d.

16. Shah MM, Wright JD. Management of endometrial cancer in young women. Clin Obstet Gynecol 2011; 54 (2): 219–225. doi: 10.1097/GRF.0b013e318218607c.

17. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 2014; 134 (2): 393–402. doi: 10.1016/ j.ygyno.2014.06.003.

18. Wang Y, Tang Z, Meng R et al. Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis. Ann Palliat Med 2021; 10 (11): 11950–11959. doi: 10.21037/apm-21-3056.

19. Masciullo V, Trivellizzi N, Zannoni G et al. Prognostic impact of hysteroscopic resection of endometrial atypical hyperplasia-endometrioid intraepithelial neoplasia and early-stage cancer in combination with megestrol acetate acetate. Am J Obstet Gynecol 2021; 224 (4): 408–410. doi: 10.1016/j.ajog. 2020.12.1210.

20. Healey JH, Brown HK. Complications of bone metastases: surgical management. Cancer 2000; 88 (12 Suppl): 2940–2951. doi: 10.1002/1097-0142 (20000615) 88: 12+<29 40:: aid-cncr10> 3.0.co; 2-w.

21. Basarir OZ, Karaca MO, Balaban K et al. Prognostic factors in endometrial cancer patients with bone metastasis. Jt Dis Relat Surg 2023; 34 (1): 207–214. doi: 10.52312/jdrs.2023.792.

ORCID authors
L. C. Gontijo 0000-0001-6162-0260
R. M. Etchebehere 0000-0002-2241-5966
L. R. M. Ferreira Souza 0000-0002-4634-8972
E. F. Candido Murta 0000-0003-4014-1345
R. Simões Nomelini 0000-0001-6591-7619
Submitted/Doručeno: 18. 12. 2023
Accepted/Přijato: 10. 4. 2024
Prof. Rosekeila Simões Nomelini, MD
Laboratory of Applied Sciences for Women (LaCam)
Department of Gynecology and Obstetrics
Federal University of Triângulo Mineiro
Av. Getúlio Guaritá 214, Bairro Abadia
Uberaga-MG 38025-440
Brazil
rosekeila@terra.com.br
Štítky
Dětská gynekologie Gynekologie a porodnictví Reprodukční medicína

Článek vyšel v časopise

Česká gynekologie

Číslo 4

2024 Číslo 4

Nejčtenější v tomto čísle
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#